An in vitro assay to quantify melphalan-induced p53-specific damage formation/repair can be used to select those patients with MM who are more likely to benefit from HDM supported by ASCT.
Meletios A Dimopoulos, Vassilis L. Souliotis, Αchilles Anagnostopoulos, Christina Bamia, Anastasia Pouli, Ioannis Baltadakis, Evangelos Terpos, Soterios Α. Kyrtopoulos, Petros P. Sfikakis
Hara Episkopou, Soterios Α. Kyrtopoulos, Petros P. Sfikakis, Maria Fousteri, Evangelos Terpos, Leon H.F. Mullenders, Vassilis L. Souliotis, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.